Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies

BACKGROUND: Obinutuzumab, a Type II anti-CD20 antibody, is used to treat follicular lymphoma. A major mode of action of obinutuzumab is antibody-dependent cellular cytotoxicity (ADCC). Knowledge of the mechanisms of resistance to obinutuzumab is important for the development of next-line strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawasaki, Natsumi, Yamashita-Kashima, Yoriko, Fujimura, Takaaki, Yoshiura, Shigeki, Harada, Naoki, Kondoh, Osamu, Yoshimura, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262784/
https://www.ncbi.nlm.nih.gov/pubmed/35218445
http://dx.doi.org/10.1007/s11033-022-07280-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262784/
https://www.ncbi.nlm.nih.gov/pubmed/35218445
http://dx.doi.org/10.1007/s11033-022-07280-w

Ejemplares similares